Skip to main content
NCBI home page
Protein & Cell logoLink to Protein & Cell
. 2011 Aug 6;2(7):554–563. doi: 10.1007/s13238-011-1073-7

Antioxidant proteins TSA and PAG interact synergistically with Presenilin to modulate Notch signaling in Drosophila

Michael F Wangler 1, Lawrence T Reiter 1, Georgianna Zimm 1, Jennifer Trimble-Morgan 1, Jane Wu 5, Ethan Bier 1,✉
PMCID: PMC3702159  NIHMSID: NIHMS442238  PMID: 21822800

Abstract

Alzheimer’s disease (AD) pathogenesis is characterized by senile plaques in the brain and evidence of oxidative damage. Oxidative stress may precede plaque formation in AD; however, the link between oxidative damage and plaque formation remains unknown. Presenilins are transmembrane proteins in which mutations lead to accelerated plaque formation and early-onset familial Alzheimer’s disease. Presenilins physically interact with two antioxidant enzymes thiol-specific antioxidant (TSA) and proliferation-associated gene (PAG) of the peroxiredoxin family. The functional consequences of these interactions are unclear. In the current study we expressed a presenilin transgene in Drosophila wing and sensory organ precursors of the fly. This caused phenotypes typical of Notch signaling loss-of-function mutations. We found that while expression of TSA or PAG alone produced no phenotype, co-expression of TSA and PAG with presenilin led to an enhanced Notch loss-of-function phenotype. This phenotype was more severe and more penetrant than that caused by the expression of Psn alone. In order to determine whether these phenotypes were indeed affecting Notch signaling, this experiment was performed in a genetic background carrying an activated Notch (Abruptex) allele. The phenotypes were almost completely rescued by this activated Notch allele. These results link peroxiredoxins with the in vivo function of Presenilin, which ultimately connects two key pathogenetic mechanisms in AD, namely, antioxidant activity and plaque formation, and raises the possibility of a role for peroxiredoxin family members in Alzheimer’s pathogenesis.

Keywords: Presenilin, Alzheimer’s disease, peroxiredoxin, Notch

Footnotes

These authors contributed equally to the work.

References

  1. Artavanis-Tsakonas S., Rand M.D., Lake R.J. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–776. doi: 10.1126/science.284.5415.770. [DOI] [PubMed] [Google Scholar]
  2. Bier E. Drosophila, the golden bug, emerges as a tool for human genetics. Nat Rev Genet. 2005;6:9–23. doi: 10.1038/nrg1503. [DOI] [PubMed] [Google Scholar]
  3. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., et al. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1–42/1–40 ratio in vitro and in vivo. Neuron. 1996;17:1005–1013. doi: 10.1016/S0896-6273(00)80230-5. [DOI] [PubMed] [Google Scholar]
  4. Boulos S., Meloni B.P., Arthur P.G., Bojarski C., Knuckey N.W. Peroxiredoxin 2 overexpression protects cortical neuronal cultures from ischemic and oxidative injury but not glutamate excitotoxicity, whereas Cu/Zn superoxide dismutase 1 overexpression protects only against oxidative injury. J Neurosci Res. 2007;85:3089–3097. doi: 10.1002/jnr.21429. [DOI] [PubMed] [Google Scholar]
  5. Brand A.H., Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401–415. doi: 10.1242/dev.118.2.401. [DOI] [PubMed] [Google Scholar]
  6. Butler A.W., Ng M.Y., Hamshere M.L., Forabosco P., Wroe R., Al-Chalabi A., Lewis C.M., Powell J.F. Meta-analysis of linkage studies for Alzheimer’s disease-a web resource. Neurobiol Aging. 2009;30:1037–1047. doi: 10.1016/j.neurobiolaging.2009.03.013. [DOI] [PubMed] [Google Scholar]
  7. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., et al. Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67–72. doi: 10.1038/nm0197-67. [DOI] [PubMed] [Google Scholar]
  8. Crowther D.C., Kinghorn K.J., Miranda E., Page R., Curry J.A., Duthie F.A., Gubb D.C., Lomas D.A. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer’s disease. Neuroscience. 2005;132:123–135. doi: 10.1016/j.neuroscience.2004.12.025. [DOI] [PubMed] [Google Scholar]
  9. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W. J., et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518–522. doi: 10.1038/19083. [DOI] [PubMed] [Google Scholar]
  10. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710–713. doi: 10.1038/383710a0. [DOI] [PubMed] [Google Scholar]
  11. Duffy J.B. GAL4 system in Drosophila: a fly geneticist’s Swiss army knife. Genesis. 2002;34:1–15. doi: 10.1002/gene.10150. [DOI] [PubMed] [Google Scholar]
  12. Fox N.C., Schott J.M. Imaging cerebral atrophy: normal ageing to Alzheimer’s disease. Lancet. 2004;363:392–394. doi: 10.1016/S0140-6736(04)15441-X. [DOI] [PubMed] [Google Scholar]
  13. Gibson G.E., Zhang H., Sheu K.R., Park L.C. Differential alterations in antioxidant capacity in cells from Alzheimer patients. Biochim Biophys Acta. 2000;1502:319–329. doi: 10.1016/S0925-4439(00)00057-0. [DOI] [PubMed] [Google Scholar]
  14. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349:704–706. doi: 10.1038/349704a0. [DOI] [PubMed] [Google Scholar]
  15. Greeve I., Kretzschmar D., Tschape J.A., Beyn A., Brellinger C., Schweizer M., Nitsch R.M., Reifegerste R. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci. 2004;24:3899–3906. doi: 10.1523/JNEUROSCI.0283-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gu F., Zhu M., Shi J., Hu Y., Zhao Z. Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice. Neurosci Lett. 2008;440:44–48. doi: 10.1016/j.neulet.2008.05.050. [DOI] [PubMed] [Google Scholar]
  17. Guillen I., Mullor J.L., Capdevila J., Sanchez-Herrero E., Morata G., Guerrero I. The function of engrailed and the specification of Drosophila wing pattern. Development. 1995;121:3447–3456. doi: 10.1242/dev.121.10.3447. [DOI] [PubMed] [Google Scholar]
  18. Haass C., De Strooper B. The presenilins in Alzheimer’s disease-proteolysis holds the key. Science. 1999;286:916–919. doi: 10.1126/science.286.5441.916. [DOI] [PubMed] [Google Scholar]
  19. Hattori F., Oikawa S. Peroxiredoxins in the central nervous system. Subcell Biochem. 2007;44:357–374. doi: 10.1007/978-1-4020-6051-9_17. [DOI] [PubMed] [Google Scholar]
  20. Iijima K., Liu H.P., Chiang A.S., Hearn S.A., Konsolaki M., Zhong Y. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer’s disease. Proc Natl Acad Sci USA. 2004;101:6623–6628. doi: 10.1073/pnas.0400895101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Krapfenbauer K., Engidawork E., Cairns N., Fountoulakis M., Lubec G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 2003;967:152–160. doi: 10.1016/S0006-8993(02)04243-9. [DOI] [PubMed] [Google Scholar]
  22. Lahiri D.K., Greig N.H. Lethal weapon: amyloid beta-peptide, role in the oxidative stress and neurodegeneration of Alzheimer’s disease. Neurobiol Aging. 2004;25:581–587. doi: 10.1016/j.neurobiolaging.2004.02.002. [DOI] [PubMed] [Google Scholar]
  23. Leutner S., Czech C., Schindowski K., Touchet N., Eckert A., Muller W.E. Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neurosci Lett. 2000;292:87–90. doi: 10.1016/S0304-3940(00)01449-X. [DOI] [PubMed] [Google Scholar]
  24. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science. 1995;269:973–977. doi: 10.1126/science.7638622. [DOI] [PubMed] [Google Scholar]
  25. Liu F., Arias-Vasquez A., Sleegers K., Aulchenko Y.S., Kayser M., Sanchez-Juan P., Feng B.J., Bertoli-Avella A.M., van Swieten J., Axenovich T.I., et al. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet. 2007;81:17–31. doi: 10.1086/518720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Marcum J.L., Mathenia J.K., Chan R., Guttmann R.P. Oxidation of thiol-proteases in the hippocampus of Alzheimer’s disease. Biochem Biophys Res Commun. 2005;334:342–348. doi: 10.1016/j.bbrc.2005.06.089. [DOI] [PubMed] [Google Scholar]
  27. Martins R.N., Turner B.A., Carroll R.T., Sweeney D., Kim K.S., Wisniewski H.M., Blass J.P., Gibson G.E., Gandy S. High levels of amyloid-beta protein from S182 (Glu246) familial Alzheimer’s cells. Neuroreport. 1995;7:217–220. doi: 10.1097/00001756-199512000-00052. [DOI] [PubMed] [Google Scholar]
  28. McLellan M.E., Kajdasz S.T., Hyman B.T., Bacskai B.J. In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci. 2003;23:2212–2217. doi: 10.1523/JNEUROSCI.23-06-02212.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mehta N.D., Refolo L.M., Eckman C., Sanders S., Yager D., Perez-Tur J., Younkin S., Duff K., Hardy J., Hutton M. Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol. 1998;43:256–258. doi: 10.1002/ana.410430217. [DOI] [PubMed] [Google Scholar]
  30. Montine T.J., Neely M.D., Quinn J.F., Beal M.F., Markesbery W.R., Roberts L.J., II, Morrow J.D. Lipid peroxidation in aging brain and Alzheimer’s disease. Free Radic Biol Med. 2002;33:620–626. doi: 10.1016/S0891-5849(02)00807-9. [DOI] [PubMed] [Google Scholar]
  31. Nowotny P., Gorski S.M., Han S.W., Philips K., Ray W.J., Nowotny V., Jones C.J., Clark R.F., Cagan R.L., Goate A.M. Posttranslational modification and plasma membrane localization of the Drosophila melanogaster presenilin. Mol Cell Neurosci. 2000;15:88–98. doi: 10.1006/mcne.1999.0805. [DOI] [PubMed] [Google Scholar]
  32. Oyama F., Sawamura N., Kobayashi K., Morishima-Kawashima M., Kuramochi T., Ito M., Tomita T., Maruyama K., Saido T.C., Iwatsubo T., et al. Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain. J Neurochem. 1998;71:313–322. doi: 10.1046/j.1471-4159.1998.71010313.x. [DOI] [PubMed] [Google Scholar]
  33. Patenaude A., Murthy M.R., Mirault M.E. Emerging roles of thioredoxin cycle enzymes in the central nervous system. Cell Mol Life Sci. 2005;62:1063–1080. doi: 10.1007/s00018-005-4541-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Perry G., Nunomura A., Hirai K., Zhu X., Perez M., Avila J., Castellani R.J., Atwood C.S., Aliev G., Sayre L.M., et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer’s and other neurodegenerative diseases? Free Radic Biol Med. 2002;33:1475–1479. doi: 10.1016/S0891-5849(02)01113-9. [DOI] [PubMed] [Google Scholar]
  35. Power J.H., Asad S., Chataway T.K., Chegini F., Manavis J., Temlett J.A., Jensen P.H., Blumbergs P.C., Gai W.P. Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer’s disease pathology. Acta Neuropathol. 2008;115:611–622. doi: 10.1007/s00401-008-0373-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T., et al. Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature. 1995;376:775–778. doi: 10.1038/376775a0. [DOI] [PubMed] [Google Scholar]
  37. Rubin G.M., Spradling A.C. Genetic transformation of Drosophila with transposable element vectors. Science. 1982;218:348–353. doi: 10.1126/science.6289436. [DOI] [PubMed] [Google Scholar]
  38. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med. 1996;2:864–870. doi: 10.1038/nm0896-864. [DOI] [PubMed] [Google Scholar]
  39. Schott J.M., Price S.L., Frost C., Whitwell J.L., Rossor M.N., Fox N.C. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology. 2005;65:119–124. doi: 10.1212/01.wnl.0000167542.89697.0f. [DOI] [PubMed] [Google Scholar]
  40. Schuessel K., Schafer S., Bayer T.A., Czech C., Pradier L., Muller-Spahn F., Muller W.E., Eckert A. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol Dis. 2005;18:89–99. doi: 10.1016/j.nbd.2004.09.003. [DOI] [PubMed] [Google Scholar]
  41. Selkoe D.J. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–766. doi: 10.1152/physrev.2001.81.2.741. [DOI] [PubMed] [Google Scholar]
  42. Shan X., Tashiro H., Lin C.L. The identification and characterization of oxidized RNAs in Alzheimer’s disease. J Neurosci. 2003;23:4913–4921. doi: 10.1523/JNEUROSCI.23-12-04913.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 1995;375:754–760. doi: 10.1038/375754a0. [DOI] [PubMed] [Google Scholar]
  44. Smith C.D., Carney J.M., Tatsumo T., Stadtman E.R., Floyd R.A., Markesbery W.R. Protein oxidation in aging brain. Ann N Y Acad Sci. 1992;663:110–119. doi: 10.1111/j.1749-6632.1992.tb38654.x. [DOI] [PubMed] [Google Scholar]
  45. Smith M.A., Nunomura A., Zhu X., Takeda A., Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal. 2000;2:413–420. doi: 10.1089/15230860050192198. [DOI] [PubMed] [Google Scholar]
  46. Struhl G., Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature. 1999;398:522–525. doi: 10.1038/19091. [DOI] [PubMed] [Google Scholar]
  47. van de Hoef D.L., Hughes J., Livne-Bar I., Garza D., Konsolaki M., Boulianne G.L. Identifying genes that interact with Drosophila presenilin and amyloid precursor protein. Genesis. 2009;47:246–260. doi: 10.1002/dvg.20485. [DOI] [PubMed] [Google Scholar]
  48. Van Gassen G., Annaert W., Van Broeckhoven C. Binding partners of Alzheimer’s disease proteins: are they physiologically relevant? Neurobiol Dis. 2000;7:135–151. doi: 10.1006/nbdi.2000.0306. [DOI] [PubMed] [Google Scholar]
  49. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., Selkoe D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gammasecretase activity. Nature. 1999;398:513–517. doi: 10.1038/19077. [DOI] [PubMed] [Google Scholar]
  50. Xia W., Zhang J., Kholodenko D., Citron M., Podlisny M.B., Teplow D.B., Haass C., Seubert P., Koo E.H., Selkoe D.J. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem. 1997;272:7977–7982. doi: 10.1074/jbc.272.12.7977. [DOI] [PubMed] [Google Scholar]
  51. Ye Y., Fortini M.E. Apoptotic activities of wild-type and Alzheimer’s disease-related mutant presenilins in Drosophila melanogaster. J Cell Biol. 1999;146:1351–1364. doi: 10.1083/jcb.146.6.1351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Ye Y., Lukinova N., Fortini M.E. Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature. 1999;398:525–529. doi: 10.1038/19096. [DOI] [PubMed] [Google Scholar]
  53. Zhou Y., Zhang W., Easton R., Ray J.W., Lampe P., Jiang Z., Brunkan A.L., Goate A., Johnson E.M., Wu J.Y. Presenilin-1 protects against neuronal apoptosis caused by its interacting protein PAG. Neurobiol Dis. 2002;9:126–138. doi: 10.1006/nbdi.2001.0472. [DOI] [PubMed] [Google Scholar]

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES